Mitochondria inside acute myeloid leukemia cells hydrolyze ATP to resist chemotherapy

• Published in: bioRxiv : the preprint server for biology
• Main Authors: Hagen, James T, Montgomery, Mclane M, Aruleba, Raphael T, Chrest, Brett R, Green, Thomas D, Kassai, Miki, Zeczycki, Tonya N, Schmidt, Cameron A, Bhowmick, Debajit, Tan, Su-Fern, Feith, David J, Chalfant, Charles E, Loughran, Thomas P, Liles, Darla, Minden, Mark D, Schimmer, Aaron D, Cabot, Myles C, Mclung, Joseph M, Fisher-Wellman, Kelsey H
• Format: Journal Article
• Language: English
• Published: United States 15.04.2024
• DOI: 10.1101/2024.04.12.589110

Despite early optimism, therapeutics targeting oxidative phosphorylation (OxPhos) have faced clinical setbacks, stemming from their inability to distinguish healthy from cancerous mitochondria. Herein, we describe an actionable bioenergetic mechanism unique to cancerous mitochondria inside acute myeloid leukemia (AML) cells. Unlike healthy cells which couple respiration to the synthesis of ATP, AML mitochondria were discovered to support inner membrane polarization by consuming ATP. Because matrix ATP consumption allows cells to survive bioenergetic stress, we hypothesized that AML cells may resist cell death induced by OxPhos damaging chemotherapy by reversing the ATP synthase reaction. In support of this, targeted inhibition of BCL-2 with venetoclax abolished OxPhos flux without impacting mitochondrial membrane potential. In surviving AML cells, sustained polarization of the mitochondrial inner membrane was dependent on matrix ATP consumption. Mitochondrial ATP consumption was further enhanced in AML cells made refractory to venetoclax, consequential to downregulations in both the proton-pumping respiratory complexes, as well as the endogenous F -ATPase inhibitor . In treatment-naive AML, knockdown was sufficient to drive venetoclax resistance, while overexpression impaired F -ATPase activity and heightened sensitivity to venetoclax. Collectively, our data identify matrix ATP consumption as a cancer-cell intrinsic bioenergetic vulnerability actionable in the context of mitochondrial damaging chemotherapy.